<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>How Is DexCom&#x27;s Performance Compared to Other Medical Device Companies? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">How Is DexCom&#x27;s Performance Compared to Other Medical Device Companies?</h2>
    <div class="badge">2025-09-09T07:28:27+00:00</div>
    <ul>
      <li>DexCom registered an 11.6% growth in non-GAAP EPS to $0.48, exceeding the Street’s expectations by 6.7%.</li>
<li>Despite its strengths, DexCom stock has plunged 16.4% from its 52-week high of $93.25 touched on Feb.</li>
<li>Further, DXCM stock has experienced a marginal 30 bps uptick in 2025, lagging behind IHI’s 7.2% gains on a YTD basis.</li>
<li>Driven by solid organic growth at home and internationally, the company’s overall topline for the quarter soared 15.2% year-over-year to $1.2 billion, surpassing the consensus estimates by 3.1%.</li>
<li>More News from Barchart - This Penny Stock Just Soared 4,000% on a Key Worldcoin Investment.</li>
<li>However, the stock has soared 13.7% over the past 52 weeks, outpacing IHI’s 7.7% returns over the past year.</li>
<li>Meanwhile, the stock has dropped by 10% over the past three months, notably underperforming the industry-focused iShares U.S.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=How Is DexCom&amp;#x27;s Performance Compared to Other Medical Device Companies?\n• DexCom registered an 11.6% growth in non-GAAP EPS to $0.48, exceeding the Street’s expectations by 6.7%.\n• Despite its strengths, DexCom stock has plunged 16.4% from its 52-week high of $93.25 touched on Feb.\n• Further, DXCM stock has experienced a marginal 30 bps uptick in 2025, lagging behind IHI’s 7.2% gains on a YTD basis.\n• Driven by solid organic growth at home and internationally, the company’s overall topline for the quarter soared 15.2% year-over-year to $1.2 billion, surpassing the consensus estimates by 3.1%.\n• More News from Barchart - This Penny Stock Just Soared 4,000% on a Key Worldcoin Investment.\n• However, the stock has soared 13.7% over the past 52 weeks, outpacing IHI’s 7.7% returns over the past year.\n• Meanwhile, the stock has dropped by 10% over the past three months, notably underperforming the industry-focused iShares U.S." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/m/40110f5b-b462-337e-8025-e1a733746894/how-is-dexcom%27s-performance.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>